Comparative proteomic analysis of atrial appendages from rheumatic heart disease patients with sinus rhythm and atrial fibrillation

Molecular Medicine Reports

Volumn 4, Issue 4, 2011, Pages 655-661

  Huang, Wen Jun ^a,b   Zhou, Rui ^a   Zeng, Xiao Rong ^b   Tan, Xiao Qiu ^b   Cheng, Zhi Hui ^a   Tang, Ming Hai ^a   Gou, Lan Tu ^a   Chen, Li Juan ^a   Tong, Ai Ping ^a   He, Yong ^a   Yang, Jin Liang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Cytoskeleton; Energy metabolism; Oxidative stress; Proteomics; Rheumatic heart disease

Indexed keywords

2,4 DIENOYL COENZYME A REDUCTASE (NADPH); ACYL COENZYME A DEHYDROGENASE; ALPHA ENOLASE; COFILIN 1; DELTA(3,5) DELTA(2,4)DIENOYL COENZYME A ISOMERASE; GLUTATHIONE PEROXIDASE 3; ISOCITRATE DEHYDROGENASE (NAD); ISOCITRATE DEHYDROGENASE (NAD) ALPHA; KERATIN TYPE I; KERATIN TYPE II; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 3; PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE A; PEROXIREDOXIN 3; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE) 1ALPHA; SUPEROXIDE DISMUTASE; TROPONIN I; UNCLASSIFIED DRUG; VERY LONG CHAIN SPECIFIC ACYL COENZYME A DEHYDROGENASE; VOLTAGE DEPENDENT ANION CHANNEL 2;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CYTOSKELETON; ENERGY METABOLISM; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYOFILAMENT; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATIC HEART DISEASE; SINUS RHYTHM; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; AMINO ACID SEQUENCE; ARRHYTHMIA, SINUS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTEOME; RHEUMATIC HEART DISEASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79957655817     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.468     Document Type: Article

References (41)

1. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 415: 219-226, 2002.
2. Kannel WB and Benjamin EJ: Status of the epidemiology of atrial fibrillation. Med Clin North Am 92: 17-40, 2008. (Pubitemid 350182405)
3. Lloyd-Jones DM, Wang TJ, Leip EP, et al: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110: 1042-1046, 2004. (Pubitemid 39319000)
4. Heeringa J, van der Kuip DA, Hofman A, et al: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 8: 949-953, 2006.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV and Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375, 2001. (Pubitemid 32424106)
6. Miyasaka Y, Barnes ME, Gersh BJ, et al: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114: 119-225, 2006.
7. Barderas MG, Dardé VM, Durán MC, Egido J and Vivanco F: Characterization of circulating human monocytes by proteomic analysis. Methods Mol Biol 357: 319-328, 2007. (Pubitemid 350183257)
8. Lai LP, Lin JL, Lin CS, et al: Functional genomic study on atrial fibrillation using cDNA microarray and two-dimensional protein electrophoresis techniques and identification of the myosin regulatory light chain isoform reprogramming in atrial fibrillation. J Cardiovasc Electrophysiol 15: 214-223, 2004.
9. De Souza AI, Cardin S, Wait R, et al: Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. J Mol Cell Cardiol 49: 853-861, 2010.
10. Mayr M, Yusuf S, Weir G, et al: Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 51: 585-594, 2008.
11. Modrego J, Maroto L, Tamargo J, et al: Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial fibrillation. J Cardiovasc Electrophysiol 21: 859-868, 2010.
12. García A, Eiras S, Parguina AF, et al: Gonzalez-Juanatey, High-resolution two-dimensional gel electrophoresis analysis of atrial tissue proteome reveals down-regulation of fibulin-1 in atrial fibrillation. Int J Cardiol: May, 2010 (E-pub ahead of print).
13. Tong A, Zhang H, Li Z, et al: Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 61: 791-802, 2008. (Pubitemid 351302035)
14. Tong A, Wu L, Lin Q, et al: Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 8: 2012-2023, 2008. (Pubitemid 351775781)
15. Poetter K, Jiang H, Hassanzadeh S, et al: Epstein, mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 13: 63-69, 1996. (Pubitemid 26139295)
16. Andersen PS, Havndrup O, Bundgaard H, et al: Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations. J Med Genet 38: E43, 2001.
17. Richard RP, Charron P, Carrier L, et al: Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227-2232, 2003. (Pubitemid 36547217)
18. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK and Aeppli DM: When compared with the general population, HCM patients have greater likelihood of developing atrial fibrillation. JAMA 281: 650-655, 1999.
19. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH and Maron BJ: Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104: 2517-2524, 2001. (Pubitemid 33107372)
20. Thijssen VL, van der Velden HM, van Ankeren EP, et al: Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Re 54: 427-437, 2002. (Pubitemid 34327921)
21. Ke L, Qi XY, Dijkhuis AJ, et al: Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. J Mol Cell Cardiol 45: 685-693, 2008.
22. Brundel BJ, Ausma J, van Gelder IC, van der Wan JJ, van Gilst WH, Crijns HJ and Henning RH: Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 54: 380-389, 2002. (Pubitemid 34327916)
23. Thijssen VL, Ausma J, Gorza L, et al: troponin I isoform expression in human and experimental atrial fibrillation. Circulation 110: 770-775, 2004. (Pubitemid 39096002)
24. Barth AS and Tomaselli GF: Cardiac metabolism and arrhythmias. Arrhythm Electrophysiol 2: 327-335, 2009.
25. Taegtmeyer H: Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 19: 59-113, 1994.
26. Barth AS, Merk S, Arnoldi E, et al: Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 96: 1022-1029, 2005.
27. Korantzopoulos P, Kolettis T, Siogas K and Goudevenos J: Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 9: 225-229, 2003.
28. Van Wagoner DR: Molecular basis of atrial fibrillation: a dream or a reality. J Cardiovasc Electrophysiol 14: 667-669, 2003.
29. Van Wagoner DR: Electrophysiological remodeling in human atrial fibrillation. Pacing Clin Electrophysiol 26: 1572-1575, 2003.
30. Shinagawa K, Derakhchan K and Nattel S: Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. Pacing Clin Electrophysiol 26: 752-764, 2003. (Pubitemid 36399486)
31. Goette A and Lendeckel U: Nonchannel drug targets in atrial fibrillation. Pharmacol Ther 102: 17-36, 2004. (Pubitemid 38429983)
32. Leonardi M and Bissett J: Prevention of atrial fibrillation. Curr Opin Cardiol 20: 417-423, 2005. (Pubitemid 41199899)
33. Lozano HF, Conde CA, Florin T and Lamas GA: Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2: 1000-1007, 2005. (Pubitemid 41372292)
34. Lee TH, Kim SU, Yu SL, et al: Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 101: 5033-5038, 2003.
35. Neumann CA, Krause DS, Carman CV, et al: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565, 2003. (Pubitemid 36975778)
36. Schroder E and Eaton P: Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: issues and considerations. Curr Opin Pharmacol 8: 153-159, 2008.
37. Araki M, Nanri H, Ejima K, Murasato Y, Fujiwara T, Nakashima Y and Ikeda M: Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 274: 2271-2278, 1999.
38. Matsushima S, Ide T, Yamato M, et al: Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarctionin mice. Circulation 113: 1779-1786, 2006. (Pubitemid 43958471)
39. Brixius K, Schwinger RH, Hoyer F, et al: Isoform-specific downregulation of peroxiredoxin in human failing myocardium Life Sci 81: 823-831, 2007.
40. Lu Z, Xu X, Hu X, et al: Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. Hypertension 51: 19-25, 2008. (Pubitemid 350307094)
41. Van Deel ED, Lu Z, Xu X, Zhu G, Hu X and Oury TD: Extracellular SOD protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med 44: 1305-1313, 2008.